Search results
Added:
3 years ago
Diabetes mellitus is one of the most common chronic diseases, affecting >30 million people in the US and 422 million worldwide.1,2 Alarmingly, both the incidence and prevalence of type 2 diabetes have doubled in the US since 1990.3 This is driven by an aging population, obesity, physical inactivity, and prolonged survival in those with diabetes, among other factors. It is estimated that…
View more
Added:
3 years ago
Cardiologists in general are strong advocates of evidence-based medicine, due to the critical nature of ischemic heart disease in patients. The use of up-to-date scientific evidence from research is paramount as the basis for making many medical decisions. There are three major advantages to using this approach. First, it offers some of the most objective ways to determine and maintain consistent…
View more
Added:
3 years ago
Cardiovascular disease is an important cause of morbidity and mortality in patients with type 1 and especially type 2 diabetes mellitus.1,2 Data from prospective studies suggest that diabetes is associated with a two to fourfold excess risk of coronary heart disease and coronary death.3–5 It was therefore hoped that controlling hyperglycemia would reduce cardiovascular disease incidence and…
View more
Added:
3 years ago
A not inconsequential number of therapeutic agents or chemical substances can increase blood pressure (BP). The degree to which BP increases determines whether a specific definitional threshold has been crossed, at which time the patient is designated as having become hypertensive. Drugs that cause hypertension do so by either causing vasoconstriction, increasing extracellular fluid (ECF) volume,…
View more
Added:
3 years ago
Dr Reinoud Knops (Academic Medical Center, Amsterdam, NL) discusses 4 years results from A Randomized Trial Of Subcutaneous Versus Transvenous Defibrillator Therapy: The PRAETORIAN Trial.
Questions:
1. Why is PRAETORIAN needed?
2. What was the design, population and endpoints of the study?
3. How long will patients be followed?
4. Were all objectives met?
5. What conclusions should be…
View more
Added:
3 years ago
Decades ago heart failure (HF) was primarily regarded as a hemodynamic disorder in an attempt to explain patients’ symptoms and disability. This hemodynamic model led to the widespread evaluation of peripheral vasodilators (to increase cardiac output by decreasing systemic vascular resistance against the failing heart). It also led to the development of novel positive inotropic agents (to…
View more
Added:
2 years ago
What are the lipid highlights from ACC.22?
In this insightful review, Dr Erin Michos (Johns Hopkins University School of Medicine, Baltimore, MD, US) talks about selected ACC.22 late-breaking clinical trials highlighting the take-home messages for clinical practice.
Trials covered in detail include:
00:28: APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting…
View more
Added:
11 months ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826).
This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that…
View more
Added:
6 years ago
Mikhail Kosiborod discusses the CVD-REAL 2 study - Lower Risk of Cardiovascular Events and Death Associated With Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs.
Filmed on-site at the American College of Cardiology congress 2018 in Orlando, USA.
View more
Added:
5 years ago
Dr Peter Jakobsson Ueda discusses the cohort study of serious adverse events with SGLT2 inhibitors, filmed byRadcliffe Cardiology on site in Munich, ESC 2018.
View more
